Anti-Cancer Agents and Biological Therapy
Clinical Pharmacology of Anti-Cancer Agents
Oncological Emergencies
Latest ESMO videos
Featured medwireNews
Cabozantinib May ‘Supplant Sunitinib’ For Metastatic Papillary RCC
CLEAR Benefit Found For Lenvatinib–Pembrolizumab In Advanced RCC
TheraP Points To Metastatic CRPC Response To Radiolabelled PSMA-Target Agent
Sotorasib Evidence Builds For KRAS-Mutated Advanced NSCLC
CheckMate 9LA Confirms Chemo Benefit With Nivolumab Plus Ipilimumab
E-Learning
ESMO E-Learning: Multimodular Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)
ESMO V-Learning: BRCA Across Tumour Types
ESMO E-Learning: Next Generation Drugs in Kidney Cancer
ESMO E-Learning: Management of Cancer Associated Thrombosis
ESMO E-Learning: Treatment of Locally Advanced NSCLC with Chemo-radiotherapy
Meeting resources
8MO - CC-90010, a reversible, potent oral bromodomain and extraterminal inhibitor (BETi) in patients (pts) with advanced solid tumours (aSTs) and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Longer follow-up from parts A & B and first reporting of part C of a phase I study
Presenter: Victor Moreno
Session: Mini Oral session
Resources:
Abstract
34MO - Outcomes according to FGFR alteration types in patients with a solid tumour treated by a pan-FGRF tyrosine kinase inhibitor in phase I/II trials
Presenter: Cedric Pobel
Session: Mini Oral session
Resources:
Abstract
33O - A phase I study to evaluate safety, pharmacokinetics (PK), and preliminary efficacy of CYH33, a phosphatidylinositol 3-kinase α (PI3Kα) inhibitor, in patients (pts) with advanced solid tumours
Presenter: Xiao Li Wei
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
Oncolytics, radiation and other combinations
Presenter: Kevin Harrington
Session: Where next with oncolytics?
Resources:
Slides
Webcast
Antibody armed oncolytic viruses
Presenter: Eric Quemeneur
Session: Where next with oncolytics?
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.